The increasingly popular nicotine pouches pose a lower risk of cancer than cigarettes, U.S. health officials said.

Shares of Philip Morris extended their recent bounce Thursday after the U.S. Food and Drug Administration authorized the marketing of 20 of the tobacco company’s Zyn nicotine pouches.

Zyn has taken the U.S. by storm. The nicotine pouch brand's boom came at an opportune time for parent company Philip Morris International, which faced years long decline in cigarette smoking. The FDA earlier this month authorized 20 Zyn products to be marketed and sold on the U.

The U.S. Food and Drug Administration (FDA), the US governmental authority responsible for regulating foods and medical products, authorized, on 16

Shares of Philip Morris International Inc. (NYSE:PM) rose 1% following the U.S. Food and Drug Administration's (FDA) authorization of 20 ZYN nicotine pouch products for marketing. The FDA's decision,

In a statement, the FDA said it has authorized the marketing and sale of Philip Morris International’s Zyn nicotine pouches. The pouches, which are placed between the lip and gum, are tobacco-free but contain nicotine. They come in different strengths and a variety of flavors such as citrus, coffee, peppermint and berry.

WASHINGTON — Federal health officials on Thursday backed the public health benefits of nicotine pouches, authorizing Philip Morris International’s Zyn to ... been available for more than a decade as FDA reviewed company data intended to show the ...

FDA authorizes Zyn nicotine pouches, citing public health benefits for adult smokers, despite concerns over flavored products' appeal to teens.

The Food and Drug Administration has authorized ZYN nicotine pouches, “making ZYN the first and only authorized nicotine pouch in the United

Analyst Lisa Lewandowski from Bank of America Securities maintained a Buy rating on Philip Morris (PM – Research Report) and keeping the price